• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Probable Nootropic-induced Psychiatric Adverse Effects: A Series of Four Cases
Conclusion Healthcare providers in general, and specifically those in the mental health and substance abuse fields, should keep in mind that nootropic use is an under recognized and evolving problem. Nootropic use should be considered in cases where there are sudden or unexplained exacerbations of psychiatric symptoms in patients who have been stable and medication adherent. It is also important to remember that most nootropics are not detected on standard drug toxicology screening tests. We have very little clinical information on how nootropics may interact with psychotropics (or other medications) and potentially cause ...
Source: Innovations in Clinical Neuroscience - December 1, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Case Series and Literature Review Current Issue Mental Disorders Psychiatry Psychopharmacology Substance Use Disorders Ampakines Armodafinil brain enhancer Cerebrolysin Citicoline cognitive enhancer homeopathic medicine natural r Source Type: research

Centaurs, Not Snake Oil
TheTechtour Healthtech Summit hosted by the International Venture Club in Lausanne is a dating event for European seed, start-up and growth companies looking for investment and for Venture capital and some Pharma/Medtech companies looking to invest. Doug Haggstrom went along to take the pulse of European digital health companies. These companies aren ’t specifically focused on Pharma as partners but it is worth paying attention to how digital health products and services are developing. Pharma developed tools and services will, after all, be compared to these companies in the marketplace and the discipline of proving sta...
Source: EyeForPharma - August 2, 2016 Category: Pharmaceuticals Authors: Tina Boggiano Douglas Haggstrom Source Type: news